Tano Biotech

Tano Biotech is a pre-clinical stage biotechnology company specializing in the development of advanced CAR-T cell therapies for the treatment of solid tumors, particularly pediatric and adult brain cancers. The company's core technology is the Tano System, a proprietary non-viral transposon-based gene delivery platform that offers a more efficient and cost-effective alternative to traditional viral vectors. This platform enables the engineering of T cells with enhanced potency and persistence to overcome the immunosuppressive microenvironment of tumors like glioblastoma. Tano Biotech's pipeline features multiple CAR-T candidates targeting validated antigens such as B7-H3 and IL13RA2. The company was founded by leading experts from St. Jude Children's Research Hospital to translate cutting-edge neuro-oncology research into clinical applications.